Atypical hemolytic-uremic syndrome.

@article{Noris2009AtypicalHS,
  title={Atypical hemolytic-uremic syndrome.},
  author={Marina Noris and Giuseppe Remuzzi},
  journal={The New England journal of medicine},
  year={2009},
  volume={361 17},
  pages={
          1676-87
        }
}
The hemolytic–uremic syndrome, which is characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal impairment, occurs most frequently in young children. Most cases are secondary to infection with Escherichia coli O157:H7 and other Shiga-toxin–producing strains. However, approximately 10% of cases are atypical and not associated with infection. This article reviews current concepts about the pathobiology of atypical hemolytic–uremic syndrome and its diagnosis and management. 
Targeting complement C5 in atypical hemolytic uremic syndrome.
  • D. Salant
  • Medicine
  • Journal of the American Society of Nephrology : JASN
  • 2011
Hemolytic uremic syndrome (HUS) is defined as the combination of microangiopathic hemolytic anemia (MAHA), acute renal failure, and thrombocytopenia. It occurs most often during outbreaks ofExpand
Atypical hemolytic uremic syndrome in high-risk neuroblastoma patient: case report
TLDR
A case report of the severe atypical hemolytic uremic syndrome in a 20 m. Expand
Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1)
We report a case of atypical hemolytic uremic syndrome (aHUS) triggered by influenza A (H1N1) in a 17-year-old boy with a mutation in the gene (CD46) encoding the transmembrane complement regulatorExpand
Hemolytic uremic syndrome.
TLDR
This review will provide the updated classification of the disease and the current diagnostic and therapeutic approaches on the complement-mediated HUS in addition to STEC-HUS which is the most common cause of the H US in childhood. Expand
Hemolytic uremic syndrome caused by enteroviral infection.
TLDR
The results of this report demonstrate that the enterovirus is the cause of atypical hemolytic uremic syndrome. Expand
Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill.
TLDR
Development of clinical prediction scores and rapid diagnostic tests based on mechanistic knowledge are needed to facilitate early diagnosis and assign timely specific treatments to patients with hemolytic uremic syndrome variants. Expand
Atypical Hemolytic Uremic Syndrome Associated With Clostridium Difficile Infection
TLDR
A case of aHUS associated with Clostridium difficile infection in a 60-year-old female patient that was successfully treated with eculizumab is presented. Expand
Postoperative atypical hemolytic uremic syndrome in nontransplant setting: A case report with review of literature
Atypical hemolytic uremic syndrome (aHUS) is a clinical diagnosis characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Postoperative aHUS inExpand
Management of hemolytic uremic syndrome.
TLDR
The therapeutic options presently available for the various forms of hemolytic uremic syndrome are reviewed and how recent knowledge has changed the therapeutic approach and prognosis of atypical HUS is shown. Expand
Postoperative Atypical Hemolytic Uremic Syndrome Treated Successfully with Eculizumab.
TLDR
A 43-year-old woman who developed aHUS two days after myomectomy was treated with the anti-C5 antibody eculizumab, which promptly improved and normalized the renal function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 130 REFERENCES
Eculizumab for atypical hemolytic-uremic syndrome.
TLDR
A case of atypical hemolytic–uremic syndrome is reported that was successfully treated with eculizumab, a humanized monoclonal antibody that blocks complement activity by cleavage of the complement protein C5, thereby preventing the generation of the inflammatory. Expand
Atypical hemolytic uremic syndrome.
TLDR
Atypical Hemolytic-uremic syndrome is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure. Expand
Eculizumab for congenital atypical hemolytic-uremic syndrome.
TLDR
A patient with congenital relapsing atypical hemolytic–uremic syndrome who was unresponsive to plasma therapy but had a response to eculizumab, a humanized monoclonal antibody against terminal complement protein C5 is reported on. Expand
Hemolytic uremic syndrome in families.
TLDR
Two groups of patients could be identified when 83 siblings with the hemolytic uremic syndrome in 41 families were examined and it is speculated that an environmental agent may have caused the syndrome in the first group, and that genetic factors may have been important in the second. Expand
Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency
TLDR
Fresh frozen plasma infusions allowed renal function to be improved and erythrocyte fragmentation to be stopped, and withdrawal of plasma therapy led to a relapse of the biological signs of HUS. Expand
[Hemolytic uremic syndrome].
  • C. Mele, M. Noris
  • Medicine
  • Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
  • 2007
TLDR
Kidney transplantation outcome is favorable in patients with MCP mutations, whereas the outcome is poor in Patients with CFH and CFI mutations due to disease recurrence, according to genetic studies. Expand
Where next with atypical hemolytic uremic syndrome?
TLDR
A comprehensive diagnostic approach is indicated for aHUS based on the latest knowledge on complement dysregulation to gain both immediate and future patient benefit by assisting in choosing more appropriate therapy for each patient. Expand
Thrombomodulin mutations in atypical hemolytic-uremic syndrome.
BACKGROUND The hemolytic-uremic syndrome consists of the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. The common form of the syndrome is triggered by infectionExpand
Atypical Hemolytic Uremic Syndrome: Update on the Complement System and What Is New
TLDR
It is important to make a comprehensive analysis and perform genetic screening of the complement system in patients with aHUS to allow a more precise approach, especially before transplantation, as complement inhibition could represent a therapeutic target in these patients who have a considerably poor prognosis. Expand
The pathogenesis and treatment of hemolytic uremic syndrome.
TLDR
The purpose of this review is to describe the pathogenesis and treatment of Stx-associated HUS, of idiopathic HUS (atypical HUS), and of the important subset of the inherited forms of HUS. Expand
...
1
2
3
4
5
...